Expanded and Enhanced Facilities and Services to Meet the Needs of More Patients, Healthcare Providers and Third Party Administrators WALTHAM, Mass., Oct 21, 2008 — PerkinElmer, Inc., a global leader in Health Sciences and Photonics, today announced that its NTD Laboratories (NTD) subsidiary relocated its headquarters, prenatal screening laboratory, and research and development (R&D) laboratory to Melville, Long Island. NTD Laboratories is a premier provider of prenatal screening for Down syndrome, trisomy 18/13 and open neural tube defects in the United States. The new facility will enable NTD to meet increased demand for advanced prenatal screening technology including the Ultra-Screen(R) free Beta hCG/PAPP-A/NT Down syndrome screen and other prenatal screening and diagnostics as PerkinElmer continues to expand its maternal healthcare offerings. The New York Department of Health certified facility will also include a maternal sample bank. “The Melville facility was designed to meet growing demand for advanced prenatal monitoring technologies, expanded capacity for analytical services and R&D, and expanded maternal health services,” said Ann-Christine Sundell, president, Genetic Screening, PerkinElmer. “For example, NTD will have the capability to translate research in pre-eclampsia to expand maternal health.” Sundell noted that the 22,000-square-foot facility will include an information technology system based on the company’s highly successful Specimen Gate(R) LIMS software used in many U.S. state laboratories to handle several hundred thousand bloodspot samples.